SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice

• Main Authors: Nerea Martos-Guillami (Author), Ander Vergara (Author), Carmen Llorens-Cebrià (Author), Aku Enam Motto (Author), Irene Martínez-Díaz (Author), Francisco Gonçalves (Author), Maria Magdalena Garcias-Ramis (Author), Estibaliz Allo-Urzainqui (Author), Alonso Narváez (Author), Sheila Bermejo (Author), Vicent Muñoz (Author), Juan León-Román (Author), Roser Ferrer-Costa (Author), Conxita Jacobs-Cachá (Author), Jordi Vilardell-Vilà (Author), María José Soler (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

IntroductionDiabetic Kidney Disease (DKD) is the main cause of end-stage renal disease in the developed world. The current treatment of the DKD with renin-angiotensin system (RAS) blockade does not totally halt the progression to end stage kidney disease. Currently, several drugs have shown to delay...